WO2015086738A3 - Hiv vaccine - Google Patents
Hiv vaccine Download PDFInfo
- Publication number
- WO2015086738A3 WO2015086738A3 PCT/EP2014/077358 EP2014077358W WO2015086738A3 WO 2015086738 A3 WO2015086738 A3 WO 2015086738A3 EP 2014077358 W EP2014077358 W EP 2014077358W WO 2015086738 A3 WO2015086738 A3 WO 2015086738A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv vaccine
- hiv
- relates
- present
- novel compositions
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel compositions of HIV-specific vaccine peptides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196620.2 | 2013-12-11 | ||
| EP13196620 | 2013-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015086738A2 WO2015086738A2 (en) | 2015-06-18 |
| WO2015086738A3 true WO2015086738A3 (en) | 2015-08-06 |
Family
ID=49725070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2014/077358 WO2015086738A2 (en) | 2013-12-11 | 2014-12-11 | Hiv vaccine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015086738A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITUB20155193A1 (en) | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Physically and chemically stable oral Givinostat suspensions |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| CN106563124A (en) * | 2016-10-19 | 2017-04-19 | 广西大学 | Application of lipoic acid as vaccine adjuvant |
| CN116999552A (en) * | 2022-04-29 | 2023-11-07 | 中山大学 | A kind of composition containing auranofin and polysulfide compound and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000052040A1 (en) * | 1999-03-04 | 2000-09-08 | Bionor Immuno As | Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| WO2013182660A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
| WO2015007337A1 (en) * | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
-
2014
- 2014-12-11 WO PCT/EP2014/077358 patent/WO2015086738A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000052040A1 (en) * | 1999-03-04 | 2000-09-08 | Bionor Immuno As | Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| WO2013182660A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
| WO2015007337A1 (en) * | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
Non-Patent Citations (3)
| Title |
|---|
| "Non-patent literature cited during the examination procedure submitted on 14.10.2005; Report - Clinical data phase II", INTERNET CITATION, 14 October 2005 (2005-10-14), pages 1 - 10, XP002717712, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP00911492&lng=en&tab=doclist> [retrieved on 20131210] * |
| ANKER LUNDEMOSE: "Exploring the Path Towards a Functional Cure for HIV", 27 November 2013 (2013-11-27), XP055134825, Retrieved from the Internet <URL:http://www.bionorpharma.com/filestore/BionorNov2013.pdf> [retrieved on 20140814] * |
| RICHARD B POLLARD ET AL: "Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial", THE LANCET INFECTIOUS DISEASES, vol. 14, no. 4, 1 April 2014 (2014-04-01), pages 291 - 300, XP055134453, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(13)70343-8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015086738A2 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208150A1 (en) | Vaccine | |
| PH12015501156A1 (en) | Pharmaceutical compositions | |
| PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| MX358099B (en) | Human immunodeficiency virus neutralizing antibodies adn methods of use thereof. | |
| EA201992133A1 (en) | PIPERIDINO-PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | |
| MY183534A (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| EA201300132A1 (en) | PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV | |
| MX2017003928A (en) | Long acting pharmaceutical compositions. | |
| MX343505B (en) | Methods and compositions for inhibiting hiv transmission. | |
| PH12016500465B1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| WO2016011324A3 (en) | 5'-triphosphate oligoribonucleotides | |
| WO2015086738A3 (en) | Hiv vaccine | |
| WO2016007540A3 (en) | Compositions and methods for treating dengue virus infection | |
| WO2016100615A3 (en) | Methods and composition for neutralization of influenza | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| WO2014210082A3 (en) | Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association | |
| WO2014025749A3 (en) | Small molecule inhibitors of viral protein interactions with human t-rna | |
| WO2015073788A3 (en) | Methods and compositions for the treatment of hcmv | |
| WO2015051268A3 (en) | Hiv protease inhibitors against picornavirus infection | |
| WO2014124092A3 (en) | Lamivudine crystalline salts | |
| WO2016112339A8 (en) | Stable formulations for the oral administration of amphotericin b and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14812211 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.09.2016) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14812211 Country of ref document: EP Kind code of ref document: A2 |